Targeted Therapies for Cancer

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

Product Pipeline

We have multiple wholly owned compounds in clinical testing.

Recently reported data at ASH 2013 included partner compounds:
SAR650984
SAR3419
BT-062 








ImmunoGen, Inc. Named One of The Boston Globe's Top Places to Work

Our Antibody-Drug Conjugate (ADC) Technology

  • Roche’s Kadcyla® is the first marketed ADC with our technology.
  • Other partners developing ADCs with our technology are Amgen, Bayer HealthCare, Biotest, Lilly, Novartis and Sanofi.    

ImmunoGen News

Read our releases...